Bullish
$OMER I'm looking to mix up the discussion which has gotten a little stale! Y'all heard of MGTA? Several other companies are also trying to make less toxic conditioning regimens for HSCT. Looks like MGTA has CD117 a preclinical asset, and therefore from what I can tell not a competitive risk. Also, their focus now seems to be centered around improving the conditioning regimen for of gene therapy. (So lets say, not currently what OMER has their eyes set on.) It would be at least 7+ years before anything like this would be approved, but what I wonder about is how broad of a scope it could/would have. nature.com/articles/s41467-... ash.confex.com/ash/2019/web...
  • 5